BRCA1 and ovarian carcinoma: Therefore, PARP inhibitors can lead to the death of cancer cells in patients with BRCA gene mutations, serving as a therapeutic purpose.[7,8] Mutations in the BRCA1/2 gene are susceptible to ovarian cancer and breast cancer.